Experts in health economics,
pricing and reimbursement
PHMR is an international team of highly qualified health economists and research scientists

The carefully curated multidisciplinary team at PHMR is comprised of highly qualified health economists and research scientists. This international collective of dedicated professionals provides in depth understanding of global markets and the capacity to work seamlessly in local languages.


Their combined insight from extensive industry specific experience in global pharmaceutical companies, academic positions and health economics consultancies ensures that PHMR’s clients always receive reliable, expert advice.

Mark Ratcliffe
Mark Ratcliffe
Mark is the founder of PHMR and has developed the company into a successful health economics, pricing and market access consultancy working with a range of top 10 pharma companies. He has a vast amount of experience in the health economics, pricing, reimbursement and market access fields. He also possesses decades of experience with major international pharmaceutical companies and previous work in senior economics research positions.
Michael Lees
Michael is involved across a range of health economics, outcomes research and market access projects at PHMR. As chief operating officer at PHMR, he is responsible for ensuring that the research delivered matches the strategic needs of our clients. Michael has extensive experience in the development of health economic models and indirect treatment comparisons, utility measurement and health valuation, strategies for collection and use of real-world data, and the development of dossiers to support HTA submission. He also has substantial experience in working with different stakeholders, including through the use of early scientific advice through HTA agencies, to lead the development of integrated evidence plans and allow for access needs to be incorporated from early in product development. Michael has led projects across many different therapeutic areas, with expertise in fields including oncology, gastroenterology, neuroscience, rare disease, and cardiovascular disease. Michael has also published his research in peer-reviewed journals and presented work at multiple international conferences. He has led educational initiatives to shape HTA policy, which involved delivering symposiums at international conferences and developing publications to support the use of innovative methodologies to demonstrate the value of new immuno-oncology medicines.
Louise Longworth
Louise Longworth
Louise has extensive experience in health economics and health technology assessment and a deep understanding of the methods of health technology assessment. As chief scientific officer at PHMR, Louise advises on the development of HTA strategy and evidence submissions in a wide range of therapeutic areas. Louise has specialist expertise in patient-reported outcomes and utility measurement. She has been a member of the EuroQol Group, the organisation responsible for the development of the EQ-5D instruments, for most of her career and currently holds a position on the Board of Directors. She has held various roles with NICE, including as Technical Adviser in the Technology Appraisals programme, leader of independent evidence reviews, member of its Decision Support Unit, and member of its Technology Appraisal Committee. Louise has published extensively on health economics methodology and HTA policy.
Cormac Sammon
Cormac Sammon
Cormac is an epidemiologist and has successfully delivered clinical and economic research projects for a variety of clients, utilising real-world data to contribute across the drug development process, from establishing the clinical and economic burden of disease to informing key parameters of cost-effectiveness models and monitoring the long-term post-marketing safety and effectiveness of drugs. Cormac’s expertise in generating and interpreting complex clinical and economic data and utilising it to demonstrate the value of emerging technologies has led him to successfully lead a broadening portfolio of health economics and outcomes research projects, including systematic and pragmatic literature reviews, economic models, and HTA submissions for NICE, SMC, and NCPE. He has been published extensively across a range of clinical, therapeutic, and methodologic areas.
Donna Fountain
Donna Fountain
Donna has extensive experience in leading and delivering a wide range of projects to support pharmaceutical companies with their health economics and outcomes research needs as well as maximising market access/reimbursement for new pharmaceutical and diagnostic interventions. As head of market access science at PHMR, she specialises in conducting systematic and targeted literature reviews to support HTA submissions and market access strategy, as well as global value dossier development, stakeholder engagement, reimbursement and landscape mapping, and peer-review manuscript development. Donna has extensive knowledge of multiple therapeutic areas, including oncology, chronic kidney disease, gastrointestinal disorders, cardiovascular disease, age-related disease, and orphan diseases. Donna has also published her research in peer-reviewed journals and presented work at multiple international conferences. Donna holds a PhD in virology and immunology from the University of Nottingham.
Gintare Cepinskaite
Gintare Cepinskaite
Gintare, Assoc CIPD, keeps HR operations aligned to the company values and brings the skills, knowledge, and energy required to ensure PHMR is a great place to work.
Ping-Ru Lo
Ping-Ru Lo
Ping has been with PHMR since its foundation helping it develop into a successful health economics, pricing and market access consultancy. Coming from a background in clinical pharmacy both in Germany and the UK, she has changed direction in order to lead the contracting and finance team and set up the internal project management structure.
Tibi
Tibi has a part-time role at PHMR. She has expertise in methods for improving health and wellbeing outcomes in workplace settings. Outside of PHMR, Tibi can usually be found networking at nearby Hampstead Heath.
Market access alerts
Our market access alerts are hand-picked items of breaking pricing, reimbursement and market access news.

Alerts